Compare CHMI & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHMI | LUNG |
|---|---|---|
| Founded | 2012 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Industrial Specialties |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 82.5M |
| IPO Year | 2013 | 2020 |
| Metric | CHMI | LUNG |
|---|---|---|
| Price | $2.76 | $1.87 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $3.00 | ★ $6.81 |
| AVG Volume (30 Days) | 198.9K | ★ 348.1K |
| Earning Date | 03-05-2026 | 02-18-2026 |
| Dividend Yield | ★ 14.81% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | $40,202,000.00 | ★ $91,664,000.00 |
| Revenue This Year | N/A | $9.21 |
| Revenue Next Year | $31.73 | $5.03 |
| P/E Ratio | $144.11 | ★ N/A |
| Revenue Growth | N/A | ★ 15.59 |
| 52 Week Low | $2.17 | $1.31 |
| 52 Week High | $3.68 | $9.37 |
| Indicator | CHMI | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 59.78 | 41.57 |
| Support Level | $2.65 | $1.68 |
| Resistance Level | $2.77 | $1.96 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 88.68 | 26.76 |
Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.